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Abstract 
It is increasingly appreciated that drug response to different cancers driven by the 
same oncogene is different and may relate to differences in re-wiring of signal 
transduction. We aimed to study differences in dynamic signaling changes within 
mutant KRAS (KRASMT), non-small cell lung cancer (NSCLC), colorectal cancer 
(CRC) and pancreatic adenocarcinoma (PDAC) cells. We used an antibody-based 
phosphoproteomic platform to study changes in 50 phosphoproteins caused by 
seven targeted anticancer drugs in a panel of 30 KRASMT cell lines and cancer cells 
isolated from 10 patients with KRASMT cancers. We report for the first time significant 
differences in dynamic signaling between CRC and NSCLC cell lines exposed to 
clinically relevant equimolar concentrations of the pan-PI3K inhibitor pictilisib 
including a lack of reduction of p-AKTser473 in CRC cell lines (P = 0.037)  and lack 
of compensatory increase in p-MEK in NSCLC cell lines (P = 0.036). Differences in 
re-wiring of signal transduction between tumor types driven by KRASMT cancers exist 
and influence response to combination therapy using targeted agents.  
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Introduction  
There are multiple examples of targeted anticancer drugs that are clinically effective 
in targeting different cancers driven by the same oncogene including the recent 
report of the activity of TRK inhibitors across a wide range of tumors driven by TRK 
fusions (1). However, there is emerging evidence related to context specificity where 
differences in signaling in different tumor types driven by the same oncogene can 
result in disparate clinical outcomes; for example, the BRAF inhibitor, vemurafenib, 
causes clinical responses in patients with V600E mutant BRAF-driven melanoma (2) 
but not colorectal cancer (3). This has been attributed to differences in EGFR 
signaling between the two tumor types (4).  
 
Mutations in the oncogene KRAS are seen across a wide range of solid tumors, such 
as pancreatic cancer (97%), colon cancer (40%) and non-small cell lung cancer 
(30%). Multiple treatment approaches to target have been proposed including post-
targeting, post-translational modification (farnesyl transferase inhibitors), 
combinatorial inhibition of down-stream pathways (5) or directly targeting the 
mutated KRAS protein (6). 
 
There have been detailed studies of down-stream signaling patterns of KRAS-
mutated (KRASMT) mutated non-small cell lung (NSCLC), pancreatic ductal 
carcinoma (PDAC) and colorectal cancer (CRC) to define patterns of signaling, 
feedback loops and optimal combination therapy (7-10).  In the light of emerging 
evidence of context specificity of drug response in cancer (3,4) and the reports that  
patients with KRASMT NSCLC and CRC respond differentially when treated with 
combinations of MEK and PI3K pathway inhibitors (11,12) we aimed to study 
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differences in dynamic signaling patterns in three diseases with frequent  KRAS 
mutations ie NSCLC, PDAC and CRC.  
 
We chose to study differences in signaling patterns in 30 KRASMT cell lines (10 
NSCLC, 10 CRC and 10 PDAC) and 10 KRASMT cells isolated from patients with 
malignant effusions. It is known that differences in the type of KRAS mutations  
between these tumor types do occur, for example, G12C mutations occur more 
frequently in KRAS mutated  NSCLC compared to CRC (5). The different KRAS 
mutations in our cell line panel are listed in Supplementary Table S1. An antibody-
based platform was used to screen changes in 50 phosphoproteins which are 
relevant to KRAS signaling and are related to targets of the drugs used as probes 
(Figure 1). We exposed the cell lines to clinically relevant concentrations of 7 
targeted anticancer drugs: AZD5363 (13) (AKT inhibitor), everolimus (m-TOR 
inhibitor), gefitinib (EGFR inhibitor), luminespib/NVP-AUY922  (14) (HSP90 inhibitor), 
pictilisib/GDC-0941 (15) (PI3K inhibitor), trametinib (MEK inhibitor), vemurafenib 
(BRAF inhibitor).  We chose these drugs as tools as they were known to inhibit 
signaling nodes related to KRAS signaling and/or where KRAS mutations were 
known to effect sensitivity to the drug.  Further, all these drugs had been used in the 
clinic and it was possible to use concentrations of the drugs that were clinically 
relevant.  We used equimolar drug concentrations across cell lines and patient 
samples rather than individual GI50 concentrations across all samples as we were 
focussed on using clinically relevant concentrations and it was not possible to 
determine GI50 of drugs in cells isolated from ascites of patients as we did not 
establish cell lines from these samples. We planned to validate any interesting 
findings in more detailed experiments. 
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Materials and Methods 
Cell lines, tissue culture and drugs 
All cell lines were obtained from ATCC (LGC Standards, Teddington, UK), Public 
Health England (Salisbury, UK), Sigma-Aldrich (St. Louis, MO, USA) or from The 
Francis Crick Institute’s Cell Services (London, UK). All drugs were sourced from 
Selleck Chemicals (Stratech, Cambridge UK).  Details of cell lines, culture media and 
concentrations of drugs used are available in the Supplementary Data. 
Baseline mutations and m-RNA expression  
Data related to whole exome sequencing baseline mRNA for 16,831 genes were 
extracted from the Cancer Cell Line Encyclopaedia (CCLE) database. Data related 
to mutations and baseline mRNA expression in 26 and 28 out of 30 cell lines, 
respectively (mutational data for COLO678, LIM-2099, LIM-1899 and PANC-1 cell 
lines were not present in the CCLE database, and mRNA data were unavailable for 
LIM-1899 and LIM-2099).  The data file 'CCLE_Expression_Entrez_2012-09-29.gct' 
and annotation file ‘CCLE_Expression.Arrays.sif_2012-10-18.txt’ were downloaded 
from the CCLE website. The data file was filtered in R Studio to only the cell lines 
used in this project, and then the values for each gene were median centered using 
the base R package. This data file was then loaded into the Broad Institute’s GENE-
E software (version 3.0.204) which was used to create Figure 2 using default 
settings. Pearson’s correlation between global mRNA expression is indicated by a 
blue-white-red color scale, normalized to the minimum correlation between cell lines 
seen (0.8367) and a hypothetical perfect correlation of 1. 
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Isolation of cancer cells from CRC and NSCLC serous effusions 
Up to 1000 ml of ascites or pleural fluid was collected from the patient and 
immunomagnetically-separated using previously published methods (16). Pleural 
and ascitic fluid were used in the study after the investigators had obtained written, 
informed consent. The tissue collection protocols were approved by the institutional 
review board and conducted in accordance with the Declaration of Helsinki.  
 
Quantification of phosphoproteins: Luminex magnetic bead suspension array 
MILLIPLEX MAP Akt/mTOR phosphoprotein kit, MILLIPLEX MAPK/SAPK signaling 
kit, MILLIPLEX MAP RTK phosphoprotein kit (48-611MAG, 48-660MAG, 
HPRTKMAG-01K respectively, MerckMillipore, Billerica, MA, USA) were combined 
with the following singleplex magnetic bead sets to produce three multiplex Luminex 
assays: phospho-NFkB, phospho-SRC, phospho-STAT3, phospho-STAT5 A/B, total 
HSP27 and GAPDH (46-702MAG, 46-710MAG, 46-623MAG, 46-641MAG, 46-
608MAG, 46-667MAG, MerckMillipore). Bio-Plex Pro phospho-PDGFRa, phospho-
PDGFRb and Akt (Thr308) (171-V50017M, 171-V50018M, 171-V50002, Bio-Rad, 
Watford, Herts, UK) were combined into a triplex assay. Ten ug of protein was 
loaded per well and manufacturers’ protocols were followed throughout.   
Additionally, an in-house multiplex Luminex assay was created utilizing a range of 
antibodies from Cell Signaling Technology (Danvers, MA, USA), targeting proteins of 
interest. These were conjugated to Luminex MagPlex Microspheres (MC100XX-01, 
Luminex, Austin TX, USA) via an xMAP Antibody Coupling Kit (40-50016, Luminex). 
A second set of antibodies, targeting phosphorylated versions of the antibodies from 
the first set, were biotinylated (Biotin Type A conjugation kit, ab102865, Abcam, 
Cambridge, UK). This home-grown assay followed the Millipore protocol; however, 
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during the optimization process it was found that small amounts of unbound biotin in 
the secondary antibody mix were binding directly to protein, increasing background. 
To offset this as much as possible the secondary antibody was added directly post- 
primary incubation and unbound protein was only washed off post-secondary 
antibody incubation. 
Phosphoprotein levels were measured on the Luminex 200 system utilising 
xPONENT v3.1 software. 
We attempted to quality control our Luminex platform.  Three test cell lines (A2780, 
HT29 and NCI-H520) were run in triplicate and each repetition was run across five 
separate 96-well plates. All plates were run in a single sitting to avoid inter-daily 
fluctuations. Baseline phospho-protein levels were measured and the coefficient of 
variation (CV) per analyte was calculated. There was considerable variation in the 
assays with the CV being >30% in at least one of the three cell lines in 12 of the 55 
analytes tested. The CV of phosphoproteins of interest such as p-MEK and p-AKT 
was <10% and <20%, respectively, in all three cell lines tested during the validation 
(Supplementary Table S2).  
Each Millipore Mapmate kit provided positive and negative lysate controls for each 
analyte (as listed in the manufacturer’s manual). These were all run once at the start 
of the project. A protein concentration titration was also carried out to assess the 
appropriate amount of protein to use in each assay. Positive controls for the home-
grown bead set were found via a literature search and were used in the optimization 
process. 
The assay platform continues to be in development and would not meet the 
standards required for clinical decision-making. However, as samples of each 
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experiment including untreated controls and samples treated with drugs were 
analyzed in the same run in order to reduce chances of variability affecting results, 
we run the untreated control sample for each cell line in each individual experiment 
thrice and calculated a mean and standard deviation for each phosphoprotein. 
Following GAPDH normalization only values for each phosphoprotein that were two 
standard deviations above or below the corresponding untreated control were 
considered to be significant. Normalizing the values of each phosphoprotein to its 
total protein in addition to normalization by loading 10 ug protein per well and 
normalizing phosphoprotein values to GAPDH would improve the quality and validity 
of the results. This was not done as it would require double the quantity of protein 
needed to analyse patient samples which we did not have. Other factors taken into 
consideration for not measuring total protein and normalizing all phosphoproteins to 
individual total proteins is that this would very significantly increase the cost and 
complexity of the screening assay. 
 
Interpretation of phosphoproteomic data 
All phosphoproteomic data were normalized to GAPDH.  Importantly, for each cell 
line, three samples of control and one sample for each drug treatment was set up.  A 
standard deviation was calculated for each control and if the drug treated sample 
had a value more than 2 standard deviations above it was classified as ‘increased’ 
and if 2 standard deviations below it was classified as ‘decreased’. If it was within 2 
standard deviations above or below the control it was considered unchanged. We 
chose to use dichotomous, increased, decreased or no change outputs as we had 
not validated the linearity of the absolute changes in phosphoprotein in our assays. 
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We ran only controls and did not treat samples in triplicate because of the cost but 
repeated specific experiments in triplicate to validate any interesting changes seen. 
 
For the purpose of analysis by logistic regression, only individual analytes which 
were considered to be significantly increased or decreased (2 standard deviations 
above or below the mean control) compared to control were used. These 
phosphorylation changes in cell lines from one tumor type were compared to the 
other two groups e.g. NSLC Vs CRC and PDAC, CRC Vs NSCLC and PDAC, PDAC 
Vs NSCLC and CRC using the generalized linear models function in R to compute 
logistic regression (RStudio, V1.1.383, RStudio,Inc). False discovery rate was 
corrected for via the Benjamini-Hochberg (BH) procedure (RStudio) and only 
changes that were significant after BH correction are mentioned in Figure 3. 
 
Quantification of p-AKT and AKT by ELISA 
Cells were lysed and phospho/Total AKT levels were measured using a phospho 
(ser473)/Total AKT whole cell lysate kit (Meso Scale Discovery, Rockville, MD, USA, 
K15100D-1) following manufacturers guidelines. 
 
Cytotoxicity and combination studies 
Growth inhibition was assessed via standard 72-hour sulforhodamine B assays by 
previously described methods (17).  
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Results 
Differences between mutations and baseline m-RNA signatures of cell lines 
Data related to mutations and baseline m-RNA signatures were available in 26 and 
28 of the 30 cell lines, respectively. Unbiased hierarchical clustering did not reveal 
that KRAS-mutant cell lines of different tumor types of origin significantly clustered 
together based on either mutation, Figure 2A or in m–RNA expression, Figure 2B. 
The data has also been fitted to each tumor type/tissue type and represented in 
Supplementary Figure 1 and Supplementary Figure 2.  
 
Phosphoproteomic screen 
Interestingly, p-MEK levels increased in more than 50% of cell lines in cells exposed 
to the PI3K inhibitor, pictilisib, AKT inhibitor, AZD5363, EGFR inhibitor, gefitinib, 
BRAF inhibitor, vemurafenib, and HSP90 inhibitor, luminespib. p-ERK levels were 
increased in more than 50% of cell lines upon exposure to the BRAF inhibitor, 
vemurafenib, AKT inhibitor, AZD5363, and EGFR inhibitor, gefitinib (Supplementary 
Table S3). These results suggest increased activation of MEK is a relatively common 
re-wiring event across multiple different drugs in the cell line panel tested.  
 
There were similarities between changes caused by drugs targeting a defined 
signaling pathway, for example, more than 50% of all the 30 cell lines showed 
reduction of p-S6 when exposed to pictilisib, AZD5363 and everolimus all targeting 
the PI3K pathway. There were differences in phosphorylation of proteins in drugs 
targeting the PI3K pathway, for example, p-AKT levels were increased in more than 
50% of cell lines exposed to AZD5353 but not pictilisib or everolimus. The increase 
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in phosphorylation of AKT despite inhibition of the target is known to be due to 
change in conformation of the drug target. 
 
 
We then tested to see if changes in each analyte were different in the three different 
tumor types when exposed to an individual drug using logistic regression and 
correcting for multiple testing (Figure 3).  A total of 39 changes in phosphorylation 
was considered significantly different across different tumor types (Table 1). 
 
Interestingly, a significantly lower number of CRC cell lines showed a reduction in 
phosphorylation of AKTSer473 when exposed to pictilisib at a clinically relevant, 
equimolar concentration compared to NSCLC and PDAC cell lines (P = 0.037). 
Conversely, p- AKTSer473 levels were reduced in NSCLC cell lines exposed to 
pictilisib compared to PDAC and CRC, although this was not statistically significant.  
Further, when exposed to pictilisib, significantly fewer NSCLC cell lines showed an 
increase in phosphorylation of MEK compared to CRC and PDAC cell lines (P = 
0.036).  We went on to further validate the findings of differential phosphoprotein 
changes between NSCLC, CRC and PDAC cell lines when exposed to pictilisib.  
 
We analyzed differences between phosphoprotein changes caused by all seven 
drugs by unbiased clustering and there were no significant differences between 
types of KRAS mutation (Supplementary Note). 
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Validation of findings related to dynamic signaling changes of the pan-PI3K inhibitor, 
pictilisib 
We chose 9 cell lines (3 each of CRC, PDAC and NSCLC) from the original panel to 
validate our results, exposing them for both 1 hr. We conducted the experiments in 
triplicate allowing more detailed assessment of fold change compared to threshold 
based binary representations used for logistic regression in the initial 1hr screen. 
The patterns of non-reduction of p-AKT in CRC cell lines and no increase in p-MEK 
levels in the NSCLC cell lines were recapitulated at 1 hr of exposure to pictilisib and 
technically validated our findings in the larger screen (Figure 4A). We also used a 
further assay (ELISA) to quantify p-AKTSer473 and total AKT at the 1 hr time-point and 
the CRC cell lines exposed to pictilisib showed a lesser reduction of p-AKTSer473 
normalized to total AKT compared to NSCLC cell lines (Supplementary Figure 3). 
 
We also determined the GI50 of pictilisib and another pan-PI3K inhibitor, buparlisib, 
exposing the 9 cell lines to increasing concentrations of pictilisib and buparlisib for 1 
hr to study changes in p-AKT and p-MEK. Changes in phosphorylation caused by 
pictilisib were concordant with that of buparlisib, suggesting that phosphoprotein 
changes were not due to the off-target effects of pictilisib (Figure 4B). It was, 
however, noted that p-MEK levels increased in the NSCLC cell line N1944 in Figure 
4B as increasing while this was not the case in Figure 3 and Figure 4A. The 
concentration of pictilisib used in experiments 3 and 4A was 96.3 nM, while 
concentrations of pictilisib used in Figure 4B were GI50 and x5 GI50, which was 
considerably higher (Supplementary Table 4) and this may account for this 
difference. 
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We studied p-MEK and p-AKT levels in cancer cells isolated from serous effusions 
(pleural effusions and ascites) in 10 patients with KRAS mutant cancers (3 NSCLC 
and 7 CRC) exposed to pictilisib for 1 hr as we had done in the 30 cell line screen. 
We found the increase in the p-MEK levels was significantly raised in 3/7 samples of 
cells isolated from patients with CRC as opposed to 0/3 samples of cells isolated 
form NSCLC. No significant reduction of p-AKT was seen in either CRC or NSCLC 
samples (Figure 4C). The number of samples were not sufficient for statistical 
analysis however the experiment provided proof of concept that it is possible to 
conduct ex-vivo assays on cancer cells freshly isolated from cancer patients. 
 
Discussion 
To our knowledge, this is the first report to study the differences in dynamic signaling 
patterns in KRASMT cell lines in an attempt to study context specificity of tumors of 
origin.  
 
Antibody-based phosphoprotein platforms have been used to study signaling output 
in cancer cells  exposed to drugs, with reverse-phase protein arrays being one of the 
more established platforms (18).  We used the antibody-bead based Luminex 
platform (19). The drugs used as probes were anticancer drugs that were either 
licensed (everolimus, gefitinib, trametinib, vemurafenib) or in phase II studies 
(AZD5363, luminespib and pictilisib). We chose to use clinically relevant 
concentrations of these drugs at human Cmax and exposed the cell lines and patient 
samples to these concentrations for 1 hr. Most phosphorylation changes occur early 
and so we chose a 1-hr time-point to reflect this, as well as the fact that 
concentrations surrounding Cmax could be maintained for 1 hr. Our aim was to study 
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differences in signal transduction at early time-points.  We acknowledge that rewiring 
of signal transduction may change at later time-points which we did not study. 
Further, we attempted to standardize the treatment conditions by exposing cells to 
drugs at 80% confluence. The cells were exposed to drugs for 1 hour so the drugs 
are unlikely to cause major differences in cell density due to cell death or growth 
inhibition, however it was not possible to rule out the effects of contact inhibition on 
signaling  in individual cell lines. We did not establish cell lines form each patient 
sample and cells derived from ascites or pleural effusions were EpCam separated 
and exposed to drugs for 1 hr in suspension. It was not possible to ascertain the 
contribution of differences in tissue culture conditions i.e adherent vs suspension in 
the results while comparing cell lines and patient samples.  The importance of PI3K 
signaling in KRASMT CRC, NSCLC and PDAC has been described previously (20). 
Co-existence of activating PIK3CA mutations with KRAS mutations in the general 
population of NSCLC, CRC and PDAC is rare (21,22).  However, the co-existence of 
PIK3CA mutations can significantly affect signaling output drug resistivity to signal 
transduction inhibitors and we were careful while choosing our panel of cell lines to 
exclude cell lines with known activating mutations in PIK3CA.  
 
KRAS mutations are found in approximately 90% of PDAC, 40% of CRC and 30% of 
adenocarcinoma subtype of NSCLC(5). Within NSCLC, a glycine to cysteine 
substitution is more common (5).  Interestingly, within NSCLC there are differences 
in outcomes for patients depending on the type of KRAS mutation. While evaluating 
differences in KRAS mutations in NSCLC, the investigators found cell lines with 
KRASGly12Cys and KRASGly12Val had decreased growth factor-dependent AKT 
activation suggesting that there are differences in signaling patterns within different 
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KRASMT cell lines (24). Further, analysis of known mutations (not exclusively KRAS) 
of the cell lines and baseline m-RNA expression available in public databases did not 
reveal the cell lines clustered significantly to tissue of origin, highlighting the 
importance of studying post-transcriptional differences such as re-wiring of signal 
transduction. 
 
Importantly, we found that in KRASMT CRC cell lines, exposure to the pan-PI3K 
inhibitor, pictilisib had a compensatory increase in p-MEK levels as well as 
differentiated themselves by not having a reduction in p-AKT levels.   In contrast 
NSCLC cell lines did not have a compensatory increase in p-MEK levels. This 
differential phosphorylation of MEK by PI3K inhibitors in KRASMT cell NSCLC and 
CRC cell lines has not been described previously.   
 
We went on to validate specific changes in cells seen in response to pictilisib by 
repeat experiments in triplicate.  We also confirmed that these changes in p-MEK 
and p-AKT occurred when a second pan-PI3K inhibitor was used, which suggested 
that the phosphoprotein changes are not due to the off-target effects of pictilisib.  
Interestingly, in cancer cells isolated from patients with KRASMT, NSCLC did not 
show activation in p-MEK, while some of the samples isolated from patients with 
KRASMT CRC did. The number of samples studied did not allow robust statistical 
analysis however shows proof of concept that such tissue can be used to study 
changes in phosphoproteins.  
 
The context specificity of oncogenes to induce cancer has been described (25). In 
the setting of KRASMT cancers, there is increasing evidence that tissue of origin also 
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dictates metabolism of branched chain amino acids (26). The signaling patterns 
within cancers cells are influenced by surrounding stromal cells as shown in KRAS 
mutant cancer cells such PDAC (27). It is possible that stromal differences in diverse 
organs lead to context specificity of KRAS mutated cancers. The findings in the 
current study of signaling in cancer cells did not take stromal influences into 
consideration and could be considered as a weakness in the experimental design. 
However, our findings are of particular significance as they suggest inherent 
differences in signaling output in KRAS mutant cancer cells sans stroma and may in 
part be responsible for context specificity of response to signaling inhibitors seen in 
clinical trials. Our study was confined to cell lines that had known KRAS mutations. 
However, it was not possible to answer the interesting question relating to context- 
specificity of signaling extending to non-KRAS mutant cell lines. 
 
Context specificity is a critical facet that influences the precision medicine paradigm. 
There is already evidence that this is clinically important to drug response, as has 
been exemplified by BRAF inhibitors (3,4). Our findings suggest there are inherent 
differences in dynamic signaling output within KRASMT cancer cells, which could 
influence drug response and should be taken into consideration while designing 
clinical trials. Finding new treatment paradigms for KRASMT cancers remains an 
urgent and unmet need. 
  
19 
 
References 
1. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, et al. Safety and Antitumor 
Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: 
Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). 
Cancer Discov 2017;7:400-9. 
2. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. 
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. 
N Engl J Med 2011;364:2507-16. 
3. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. 
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. 
N Engl J Med 2015;373:726-36. 
4. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. 
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through 
feedback activation of EGFR. Nature 2012;483:100-3. 
5. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable 
RAS: Mission possible? Nat Rev Drug Discov 2014;13:828-51. 
6. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors 
allosterically control GTP affinity and effector interactions. Nature 
2013;503:548-51. 
7. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. 
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and 
PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6. 
8. Lito P, Saborowski A, Yue J, Solomon M, Joseph E, Gadal S, et al. Disruption 
of CRAF-mediated MEK activation is required for effective MEK inhibition in 
KRAS mutant tumors. Cancer Cell 2014;25:697-710. 
20 
 
9. Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, et al. RAF 
suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell 
Rep 2014;8:1475-83. 
10. Manchado E, Weissmueller S, Morris JPt, Chen CC, Wullenkord R, Lujambio 
A, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. 
Nature 2016;534:647-51. 
11. Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, 
et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor 
buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib 
(GSK1120212) in patients with selected advanced solid tumors. Clin Cancer 
Res 2015;21:730-8. 
12. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara 
DR, et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. 
Clin Cancer Res 2015;21:739-48. 
13. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. 
Preclinical pharmacology of AZD5363, an inhibitor of AKT: 
pharmacodynamics, antitumor activity, and correlation of monotherapy activity 
with genetic background. Mol Cancer Ther 2012;11:873-87. 
14. Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-
AUY922: a novel heat shock protein 90 inhibitor active against xenograft 
tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60. 
15. Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, et al. Biological 
properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from 
PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther 
2009;8:1725-38. 
21 
 
16. Carden CP, Stewart A, Thavasu P, Kipps E, Pope L, Crespo M, et al. The 
association of PI3 kinase signaling and chemoresistance in advanced ovarian 
cancer. Mol Cancer Ther 2012;11:1609-17. 
17. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, et al. 
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 
90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin 
in human ovarian cancer xenograft models. Clin Cancer Res 2005;11:7023-
32. 
18. Lu Y, Ling S, Hegde AM, Byers LA, Coombes K, Mills GB, et al. Using 
reverse-phase protein arrays as pharmacodynamic assays for functional 
proteomics, biomarker discovery, and drug development in cancer. Semin 
Oncol 2016;43:476-83. 
19. Stewart A, Banerji U. Utilizing the Luminex Magnetic Bead-Based Suspension 
Array for Rapid Multiplexed Phosphoprotein Quantification. Methods Mol Biol 
2017;1636:119-31. 
20. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-
kinase pathway in cancer. Nat Rev Drug Discov 2009;8:627-44. 
21. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al. 
PIK3CA mutations frequently coexist with RAS and BRAF mutations in 
patients with advanced cancers. PLoS One 2011;6:e22769. 
22. Scheffler M, Bos M, Gardizi M, Konig K, Michels S, Fassunke J, et al. PIK3CA 
mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, 
prognostic impact and incidence of prior malignancies. Oncotarget 
2015;6:1315-26. 
22 
 
23. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, et al. PIK3CA 
mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK 
and mutant KRAS signaling. Cancer Res 2010;70:6804-14. 
24. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, et al. 
Effect of KRAS oncogene substitutions on protein behavior: implications for 
signaling and clinical outcome. J Natl Cancer Inst 2012;104:228-39. 
25. Schneider G, Schmidt-Supprian M, Rad R, Saur D. Tissue-specific 
tumorigenesis: context matters. Nat Rev Cancer 2017;17:239-53. 
26. Mayers JR, Torrence ME, Danai LV, Papagiannakopoulos T, Davidson SM, 
Bauer MR, et al. Tissue of origin dictates branched-chain amino acid 
metabolism in mutant Kras-driven cancers. Science 2016;353:1161-5. 
27. Tape CJ, Ling S, Dimitriadi M, McMahon KM, Worboys JD, Leong HS, et al. 
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation. 
Cell 2016;165:1818. 
23 
 
 
Drug 
(target) 
NSCLC vs CRC + PDAC 
 
CRC vs NSCLC + PDAC 
 
PDAC vs NSCLC + CRC 
Increased 
Not 
increased 
Decreased 
Not 
decreased 
 
Increased 
Not 
increased 
Decreased 
Not 
decreased 
 
Increased 
Not 
increased 
Decreased 
Not 
decreased 
AZD5363 
(AKT) 
RB  IR 
SRC 
    STAT5   IR    
Everolimus 
(m-TOR) 
  SRC 
S6K 
  MEK RB    C-MET 
IRS1 
   
Gefitinib 
(EGFR) 
     m-TOR  IRS1       
Luminespib 
(HSP90) 
 MEK PTEN     IGF1R 
IRS1 
  B-Catenin  C-KIT  
Pictilisib 
(PI3K) 
 m-TOR 
MEK 
CHK1 
CHK2 
PTEN 
  GSK3B   PRAS40 
AKT 
     
Trametinib 
(MEK) 
  PDGFRB 
SRC 
       B-Catenin 
CHK2 
   
Vemurafenib 
(KRAS) 
FGFR1 
HER3 
IR 
STAT5 
  m-TOR   CHK1      PRAS40 
C-KIT 
 
 
Table 1. Significant differences in phosphoprotein changes between tumor types 
 
Changes in phosphorylation of proteins that were increased or decreased upon exposure to different drugs but were significantly different 
from cells derived from different tumor types i.e. NSCLC, CRC and PDAC upon logistic regression corrected for multiple testing. 
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Legends to Figures  
 
Figure 1 
The figure shows the network of interactions between the phosphoproteins studied in this 
project and the targets of the drugs used and KRAS. Targets of the drugs are shown as 
red nodes.  
 
Figure 2 
Baseline characteristics of cell line panel 
A) Heat map of mutations in the cell line panel, using agglomerative average linkage 
clustering with hamming distance.  Black = a mutated gene. Cell lines are labelled on the 
left with their tissue type. B)  GENE-E clustered heat map of global Pearson correlations 
between basal mRNA, with tissue type annotation. The minimal global Pearson correlation 
between cell lines is 0.8347, reflecting similarities in expression of the majority of the 
16,381 genes analyzed, for example, due to house-keeping gene expression. Pearson 
correlations are indicated by a blue-white-red color scale normalized to this minimum 
correlation of 0.8347 and maximized to a perfect correlation of 1. Overall, the three tissue 
types are mixed throughout the correlation matrix: the cell lines do not cluster together with 
other cell lines of the same tissue in the dendrogram. The highest correlations between 
mRNA profiles (denoted by a pink-red color in the heat map) are seen between the 
following cell lines: ASPC1, HPAFII, CAPAN1, CAPAN2, CFPAC1 and HUPT4, all of 
which are pancreatic. However, the remaining pancreatic cell lines are scattered 
throughout the dendrogram and have a comparatively low correlation with this cluster of 
cell lines.  
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Figure 3 
Results of phosphoproteomic screen 
Changes in phosphorylation in cell lines exposed to targeted anticancer drugs. For each 
analyte, phosphorylation changes had to be first separated out into ‘up regulated vs not’ 
and ‘down-regulated vs not’ giving binary ‘1/0’ categories. Logistic regression compared 
the number of ‘1s’ in one tumor type to the ‘1s’ in the other two tumor types combined, 
repeated for each tumor/drug/analyte configuration and was corrected for multiple testing. 
The color green and symbol -1 denotes that the levels of the phosphoprotein were 2 
standard deviations below the control; the color red and symbol 1 denote levels of 
phosphoprotein that were 2 standard deviations above control and cells with no color and 
symbol 0 denote values between 2 standard deviations above and below control. Only 
changes that were significantly different between any of the three tumor types by logistic 
regression have been depicted. 
 
 
Figure 4  
Validation of findings in phosphoproteomic screen 
A) Changes in phosphorylation caused by the pan-PI3K inhibitor, pictilisib.  Nine cell lines 
were exposed to pictilisib in 3 separate experiments and the phosphorylation of p-MEK 
and p-AKT was measured to confirm findings in the initial screen. B) Changes in 
phosphorylation caused by equitoxic concentrations of PI3K inhibitors pictilisib and 
buparlisib for 1 hr at GI50 and x 5 GI50 concentration for 1 hr. The phosphoprotein changes 
caused by both inhibitors are concordant. C) Changes in phosphorylation in 10 samples of 
cancer cells isolated from patients with KRASMT cancers exposed to pictilisib. 1, -1 indicate 
changes more than 2 standard deviations above or below control, respectively and 0 
indicates changes between 2 standard deviations above or below the control. None of the 
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NSCLC samples showed a significant increase in p-MEK while 3/7 CRC samples did. 
Significant reductions in p-AKT levels were not seen in NSCLC or CRC samples.  The 
concentrations of drugs used for the cell lines are detailed in the Supplementary Data. The 
patient-derived cell lines were exposed to a concentration of pictilisib of 96.3 nM. 
The histograms in A and B represent means and the error bars represent standard 
deviation.   
 
 
